Objective: Based on the TAX 327 Phase III trial, docetaxel (DTX)-based chemotherapy is the standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC). However, some heterogeneity is observed in clinical practice. The present study aimed to evaluate the outcomes of a weekly low-dose DTX regimen, which is clinical practice at our institution, and to compare it with the standard triweekly DTX use in the TAX 327 trial. Materials and methods: We reviewed the charts of all mCRPC patients treated with DTX 30 mg/m 2 weekly on Days 1 and 8 of a 3-week cycle and prednisolone 5 mg twice daily between January 2006 and February 2014 in our hospital. Results: In the first-line setting, 19 patients with mCRPC received weekly DTX chemotherapy. The median four cycles of treatment were given in our cohort. The median follow-up period from the start of chemotherapy was 27.9 months (range 5.4e67.2months). The prostate-specific antigen (PSA) response rate was 47.3%, and the median overall survival was 15.8 months (range 1.2e34.5 months). The main toxicities were anemia (57%), fatigue (26%), and neuropathy (10%). Two patients had different Grade 3 to 4 adverse events (neutropenia and anemia). Our results revealed initial PSA <100 ng/mL, long duration (>12 months) of response to primary hormone therapy, rechallenge, and a higher accumulation dose of DTX were associated with good prognosis. Conclusion: For Taiwanese mCRPC patients, weekly DTX 30 mg/m 2 is an efficient regimen for disease control with relatively low Grade 3 or 4 hematological adverse effects. The proper treatment duration of DTX therapy for mCRPC in Taiwanese patients is still uncertain, so further research is needed.
Introduction
The incidence of prostate cancer has been rapidly increasing in Taiwan: in 2011, prostate cancer became the fifth most common cancer in males, and in 2013, it resulted in 1207 deaths. 1 Moreover, about half of Taiwanese patients present with locally advanced or metastatic disease upon diagnosis, which is quite different from that in Western countries, where localized disease is found in most new cases. 2 The standard initial treatment for metastatic prostate cancer is androgen deprivation therapy, which leads to an improvement in bone pain, a regression of soft-tissue metastases, and a reduction in serum levels of prostate-specific antigen (PSA). 3 However, most patients eventually develop metastatic castrationresistant prostate cancer (mCRPC). In 2004, the US Food and Drug Administration approved docetaxel (DTX) for the treatment of mCRPC. The triweekly regimen (75 mg/m 2 every 3 weeks) demonstrated a survival benefit in the TAX 327 and Southwest Oncology Group (SWOG) 9916 Phase III trials and is now the standard first-line therapy for symptomatic mCRPC patients. However, hematologically adverse events seem to be more frequent in Asian patients than in the TAX 327 patients, especially among elderly patients. 4 In the TAX 327 study, 1006 patients with advanced prostate cancer received 5 mg prednisone twice daily plus 12 mg/m 2 mitoxantrone every 3 weeks, 75 mg/m 2 DTX every 3 weeks, or 30 mg/m 2 DTX once weekly for 5 of every 6 weeks. Median survival in the two DTX arms was 18.9 months and 17.4 months, versus 16.5 months in the mitoxantrone group. The triweekly higher-dose DTX regimen was associated with more neutropenia events than the weekly low-dose regimen.
No clear consensus exists regarding the optimum duration and dosage of DTX chemotherapy in Taiwanese patients to minimize side effects with equal efficacy. Moreover, standard triweekly DTX therapy often causes hematologically adverse events and leads to the discontinuation of chemotherapy in our clinical practice. To reduce adverse events and their related mortality, we used a lowdose regimen with DTX 30 mg/m 2 on Days 1 and 8 of a 3-week cycle and prednisolone 5 mg twice daily. This study aimed to retrospectively assess the differences in efficacy and adverse events in this low-dose DTX protocol.
Materials and methods
After approval was obtained from the institutional research board, a retrospective analysis was performed of all mCRPC patients treated with DTX 30 mg/m 2 on Days 1 and 8 of a 3-week cycle and prednisolone 5 mg twice daily at a center between 2006 and 2013. Data from 19 consecutive patients were retrospectively analyzed. Eligible patients were diagnosed as having metastatic adenocarcinoma of the prostate and castration resistance. Castration-resistant prostate cancer (CRPC) was defined as a serial increase in serum PSA level on three consecutive examinations, 2 weeks apart, resulting in two 50% increases over the nadir with PSA >2.0 ng/mL or the enlargement of any lesion on radiographic examination, even with a castration level of serum testosterone. PSA was used as the primary criterion to assess response and progression; radiography and bone scans were used as additional data. PSA response was defined as a decline of 50% from the baseline value. PSA progression was defined as a 50% increase from the baseline in nonresponders or a 50% increase from the nadir in responders. Progression-free survival and overall survival (OS) were measured from the date of initiation of DTX to the date of the first event (progression or death) or the last follow up. Toxicity was graded according to the Common Terminology Criteria for Adverse Events (version 3.0, 2003). Duration of response to primary hormone therapy was defined as the time from the date of initiation of hormone therapy against prostate cancer to the date of CRPC diagnosis. All statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA). Analyses were performed using the Cox proportional hazards regression model. A p value < 0.05 was considered significant.
Results
This study enrolled a total of 19 Taiwanese patients between January 2006 and February 2014. The characteristics of the patients are listed in Table 1 . The median age was 69 years (range 50e83 years). All patients had an ECOG performance status of 0e2. The median total Gleason score was 9 (7e10). Two patients had undergone radical prostatectomy, and four patients received definitive (n ¼ 2) or salvage (n ¼ 2) radiation therapy. Prior to DTX treatment, all patients had received hormone therapy, including castration and anti-androgen agents (bicalutamide and flutamide). The median serum pre-DTX-treatment PSA level was 102 ng/mL (range 14.7e865 ng/mL). The patients had metastatic lesions in bone (n ¼ 18; 94.7%), lymph nodes (n ¼ 10; 52.6%), or visceral metastases (n ¼ 4; 21%). The median follow-up period from the start of chemotherapy was 27.9 months (range 5.4e67.2 months). The median number of cycles administered was 4 (range 1e8). The PSA response rate was 47.3%, and the median duration of response was 7.6 months. The median progression-free survival was 5.1 months [95% confidence interval (CI) 3.9e6.3], and the median OS was 15.8 months (95% CI 12.0e19.4). Three patients received rechallenge with the same dose, and two of them had PSA response. The responses to treatment are summarized in Table 2 .
Three patients stopped chemotherapy before the planned four cycles: two of them because of disease progression and one because of treatment toxicity and infection. No patient required a dose reduction before completing their course. One patient died of infection during chemotherapy. The most common adverse effects in our cohort were nail change (26%), fatigue (26%), and vomiting (21%). Only Grade III neutropenia and Grade III anemia were observed. The chemotherapy toxicities of our patients and the TAX 327 trial patients are summarized in Table 3 .
To identify prognostic factors associated with OS, we performed analyses with Cox proportional hazards regression models (Table 4 ). Initial PSA <100 ng/mL, duration of response to primary hormone therapy >12 months, and DTX rechallenge were associated with good prognosis, and a higher accumulation dose of DTX also showed a trend of prolonged survival.
Discussion
In 2004, the TAX 327 and SWOG 9916 studies showed DTX chemotherapy had a significant survival benefit for men with mCRPC. 5, 6 The TAX 327 study randomly assigned 1006 men with mCRPC to receive DTX 75 mg/m 2 every 3 weeks, DTX 30 mg/m 2 weekly for 5 of 6 weeks, or mitoxantrone 12 mg/m 2 every 3 weeks, each with prednisone 5 mg twice daily. The study showed significantly longer survival for the q3w arm. The SWOG trial also showed that treatment of CRPC with estramustine and DTX q3w results in longer median survival than treatment with mitoxantrone and prednisone. Because of these two important trials, DTX q3w is now the first-line standard of treatment for patients with CRPC. However, hematological toxicity, especially neutropenia and neutropenic sepsis, is always a concern with chemotherapy regimens employing high-dose DTX, reaching even higher than 72%. 7 Lowdose DTX with weekly or biweekly schedules is more tolerable, and many studies have demonstrated survival benefits with lower hematological toxicity. 8e13 To date, the present study is the only one that analyzes the efficacy and adverse events of weekly DTX chemotherapy in Taiwanese CRPC patients. The patient characteristics, such as age and baseline PSA, were similar to those in the TAX 327 trial, but our cohort had more patients (8) with high Gleason scores (74% vs. 31%) and low median accumulation dose (330 mg/m 2 vs. 712.5 mg/ m 2 ). Our regimen had comparable response rates, pain relief rates, and duration of response with those of the TAX 307 trial. However, the median OS of our patients (15.7 months) was inferior to that in the q1w (17.4 months) and q3w (18.9 months) arms of the TAX 327 trial. A high Gleason score and low accumulation dose are believed to be adverse prognostic factors, 14, 15 so they may have caused the difference in OS between the TAX 327 trial and our study. Three patients in our study received DTX rechallenge with variable cycles (5e8), and two of them had PSA response and relatively longer OS. This data suggests that more cycles of the weekly low-dose DTX regimen are probably needed to achieve better oncological outcomes.
Compared with the triweekly regimen of the TAX 327 trial, our weekly regimen caused few cases of adverse events, such as fatigue, diarrhea, peripheral neuropathy, vomiting, and Grade 3 or 4 neutropenia. Our weekly regimen seems to be a safe treatment for fragile patients. Avoiding treatment complications is an important consideration for CRPC patients who have undergone DTX chemotherapy because two-thirds of prostate-cancer-related deaths occur in men aged 75 years or older and many patients have comorbid disorders. 16 Moreover, treatment options following DTX chemotherapy for patients with mCRPC are rapidly increasing, and new agents have been shown to improve the survival of these patients. These agents include cabazitaxel, 17 abiraterone, 18 enzalutamide, 19 and radium-223. 20 These advances have changed the standard of care, and additional studies are needed to find the best way of giving them either in combination or as sequential single agents. For first-line treatment, patient safety and complication avoidance are becoming more and more important.
To improve the strategy of weekly DTX chemotherapy, identifying prognostic factors is a key step. We analyzed our patients' data to explore the prognostic factors for survival outcomes in Taiwanese patients. The result demonstrated that initial PSA <100 ng/mL, duration of response to primary hormone therapy >12 months, and DTX rechallenge were associated with good prognosis, and a higher accumulation dose of DTX also showed a trend of prolonged survival. Several studies focused on prognostic factors in Asian CRPC patients who had undergone a standard dose of DTX chemotherapy, and concluded that alkaline phosphatase value, visceral metastasis, PSA doubling time, baseline hemoglobin concentration, cycles of chemotherapy, and time to castration resistance were independent prognostic factors. 14, 21 Some of these markers were not available in our patients, so they were not used in our study. Combining these prognostic factors may further refine the risk stratification model and help in selecting the appropriate time for the initiation and duration of DTX chemotherapy. Once patients progress on androgen deprivation therapy, we suggest DTX chemotherapy should be offered regardless of symptoms to maximize DTX accumulation dose with low initial PSA levels. Our regimen should be more tolerable in asymptomatic patients.
This study had several limitations. First, it was a single-center study with a small number of patients. Second, it was a retrospective study, but some important data were unavailable in the chart review. Finally, the observation period may not have been long enough to determine the actual OS pattern. Despite these limitations, however, the results suggest that DTX 30 mg/m 2 weekly is an efficient regimen with relatively few Grade 3 or 4 hematological adverse events. To achieve the best clinical benefit with few adverse events, future prospective studies should be performed to determine the appropriate timing and cycles of this weekly DTX regimen.
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